DCPH Deciphera Pharmaceuticals Inc.

64.96
-0.44  -1%
Previous Close 65.4
Open 65.68
Price To Book 5.48
Market Cap 3,315,812,524
Shares 51,043,912
Volume 232,930
Short Ratio
Av. Daily Volume 578,007
Stock charts supplied by TradingView

NewsSee all news

  1. Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones

    - Ripretinib Marketing Applications Submitted to Health Canada and Australia's Therapeutic Goods Administration for Patients with Advanced GIST via the U.S. FDA's Project Orbis Pilot Program - - Commercial

  2. Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer,

  3. Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

    - Application is Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program - - Positive Results from Company's INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced

  4. Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors

    - Former CEO of Array BioPharma Brings Expertise in Oncology Drug Development and Commercialization - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms

  5. Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman

    Accomplished Former COO of Deloitte Brings Extensive Strategic, Operational and Business Expertise Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 update due 2020.
DCC-3014
Solid tumors or hematological malignancies
NDA filing announced December 16, 2019.
Ripretinib DCC-2618 - INVICTUS
Gastrointestinal Stromal Tumors (GIST) - fourth-line
Phase 3 enrolment to be completed 2H 2020.
DCC-2618 - INTRIGUE
Gastrointestinal Stromal Tumors (GIST) - second-line
Phase 1b trial complete.
Rebastinib
Breast Cancer
Phase 1b/2 data to be presented 2020.
Rebastinib and paclitaxel
Solid tumors
Phase 1b/2 data to be presented 2020.
Rebastinib and carboplatin
Solid tumors
Phase 1 updated data presented at AACR-NCI-EORTC October 29, 2019.
Ripretinib DCC-2618
Gastrointestinal Stromal Tumors (GIST) - second-fourth line

Latest News

  1. Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones

    - Ripretinib Marketing Applications Submitted to Health Canada and Australia's Therapeutic Goods Administration for Patients with Advanced GIST via the U.S. FDA's Project Orbis Pilot Program - - Commercial

  2. Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer,

  3. Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

    - Application is Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program - - Positive Results from Company's INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced

  4. Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors

    - Former CEO of Array BioPharma Brings Expertise in Oncology Drug Development and Commercialization - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms

  5. Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman

    Accomplished Former COO of Deloitte Brings Extensive Strategic, Operational and Business Expertise Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of

  6. Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting

    - Preliminary Anti-tumor Activity Observed in Initial Diffuse-type TGCT Patients Treated with DCC-3014 in Ongoing Phase 1 Study - - DCC-3014 was Generally Well Tolerated with No Reported Grade 3 or Higher TEAEs in

  7. Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that members of the management team will present

  8. Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results

    - Ripretinib Granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors (GIST) - - Clinical Progress Across

  9. Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    - Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line Gastrointestinal Stromal Tumors (GIST) Cohort from the Phase 1 Study of Ripretinib in Patients Receiving 150 mg QD as Starting Dose - -

  10. Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    - Combination of Rebastinib and Paclitaxel Exhibited Encouraging Preliminary Anti-tumor Activity Across Treatment Arms in the Ongoing Phase 1b/2 Clinical Study - - DCC-3116 Represents a Differentiated Approach to

  11. Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 4, 2019

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its third quarter 2019

  12. Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer

    Accomplished CMO Brings Deep Clinical Drug Development Expertise from Leading Biotech and Pharma Companies Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key

  13. Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the late-breaking presentation of results from the INVICTUS

  14. Deciphera Pharmaceuticals, Inc. to Present at the 2019 Cantor Global Healthcare Conference

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive

  15. Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that data from the Company's INVICTUS pivotal

  16. Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Common Stock

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced